Frontier IP Group - Appointment of Chief Financial Officer
RNS: 9058C
AIM: FIPP
Frontier IP Group plc
("Frontier IP" or the "Group")
Appointment of Chief Financial Officer
Frontier IP, a specialist in commercialising intellectual property, is pleased to announce the appointment of
Shaun is an ICAEW-qualified chartered accountant with extensive experience in corporate finance, scaling businesses, and delivering successful exits. He brings more than 20 years' experience in senior financial leadership roles, including more than 15 years at board-level, with a focus on fundraising, mergers and acquisitions ("M&A"), and growth strategy.
Shaun has held board-level positions in a number of private and public companies, most recently as Chief Financial Officer at Actimed Therapeutics, where he co-led a Series B equity funding round securing a multi-million investment for clinical programmes. Prior to this Shaun served as Chief Financial Officer of Destiny Pharma for six years between 2018 and 2024. Before transitioning to executive roles, Shaun gained extensive experience in financial consultancy and senior corporate finance roles including at HSBC Investment Banking, BDO LLP, Evolution Securities plc and PwC.
He is currently a non-executive director of spirits group Distil plc.
Further to the announcement made by the Company on
Further regulatory disclosures
The following additional information is provided in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies.
|
Current directorships and/or partnerships |
Former directorships and/or partnerships within the last five years |
|
Distil plc
|
Destiny Pharma Limited
Destiny Pharma (Brighton) Limited
Destiny Pharma EU Limited ( |
ENQUIRIES
|
Frontier IP Group Plc
Company website: www.frontierip.co.uk |
M: 07415 888 425 |
|
Allenby Capital Limited (Nominated Adviser) |
T: 0203 328 5656 |
|
Singer Capital Markets (Broker) |
T: 0207 496 3000
|
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE